GLP-1 Prescription Eligibility & Medical Criteria

Q: What is the minimum BMI required to be prescribed GLP-1?

FDA-approved GLP-1 medications require BMI ≥30 or BMI ≥27 with weight-related comorbidities (hypertension, sleep apnea, diabetes). Compounded formulations may follow similar frameworks, though prescribing practices vary. Your provider evaluates overall metabolic health, not BMI alone.

Q: Can I be prescribed GLP-1 if I have prediabetes but no type 2 diabetes diagnosis?

Some providers prescribe GLP-1 off-label for prediabetes (A1C 5.7–6.4%), particularly with additional risk factors like metabolic syndrome or family history. Insurance coverage is less predictable for prediabetes. Discuss individual risk factors with your provider to evaluate whether GLP-1 aligns with your health plan.

Q: How much does GLP-1 treatment cost at PlexusDx?

PlexusDx compounded semaglutide injection costs $179–$229/month, oral semaglutide from $209/month, and compounded tirzepatide injection $229–$309/month. Precision Peptide Genetic Test adds $99 or $298 standalone. Prices vary by dosage and formulation; consultation with a provider determines optimal option for your needs.

Q: What happens if I have a family history of thyroid cancer—am I automatically disqualified?

Family history of medullary thyroid carcinoma (MTC) or MEN2 is a contraindication; GLP-1 should not be used. Your provider will screen for personal or family MTC/MEN2 before prescribing. Other thyroid cancers do not automatically exclude GLP-1, but your provider must confirm medical clearance.

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Obtaining a GLP-1 prescription requires meeting specific medical criteria and working with a qualified healthcare provider. Current FDA-approved GLP-1 medications are indicated for type 2 diabetes, cardiovascular risk reduction, or chronic weight management—though prescribing practices vary by provider, insurance, and clinical presentation. Understanding these pathways helps patients approach treatment discussions with realistic expectations.

Beyond standard eligibility markers like BMI or A1C levels, modern precision medicine considers individual metabolic patterns, biomarker profiles, and genetic factors that influence how patients respond to GLP-1 therapy. PlexusDx supports this personalized approach by helping patients understand their unique peptide pathway genetics, which may provide context for provider conversations about whether GLP-1 treatment aligns with their metabolic profile.

Primary Medical Indications and Diagnostic Requirements

GLP-1 agonists are FDA-approved for type 2 diabetes (A1C ≥6.5%), established cardiovascular disease, or chronic weight management in adults with BMI ≥30 or ≥27 with weight-related conditions. Providers evaluate fasting glucose, lipid panels, and metabolic history to confirm indication. Each medication carries specific label requirements; compounded formulations may follow similar clinical frameworks when prescribed off-label.

Insurance coverage often requires documented failure of first-line therapy (metformin for diabetes) or specific BMI thresholds. Medicare has expanded coverage criteria over recent years. Providers increasingly consider individual risk stratification—including family history of diabetes, prediabetic ranges, or metabolic syndrome—when evaluating whether treatment aligns with long-term health goals, even in borderline cases.

Biomarker and Metabolic Screening Framework for GLP-1 Candidacy

Comprehensive metabolic assessment informs GLP-1 prescribing decisions. Standard screening includes fasting glucose, HbA1C, lipid panel, kidney function (eGFR), liver enzymes, and body composition. Additional markers—insulin resistance (HOMA-IR), C-peptide levels, inflammatory markers (CRP)—provide deeper metabolic context and help providers identify whether insulin dysregulation or glucose control is the primary driver of a patient's condition.

Biomarker	Relevance to GLP-1 Candidacy
HbA1C ≥6.5% (or 5.7–6.4%)	Confirms diabetes or prediabetes; guides treatment intensity and type.
Fasting Glucose >100 mg/dL	Indicates insulin secretion challenges; reflects daily metabolic stress.
HOMA-IR >2.5	Suggests insulin resistance; GLP-1 may improve sensitivity over time.
eGFR <30 mL/min/1.73m²	Contraindication or caution; dose adjustment required; monitor kidney function.
Triglycerides >200 mg/dL	Indicates dyslipidemia; GLP-1 often improves lipid profile alongside weight loss.

How Genetic Predispositions Shape Individual GLP-1 Response Patterns

Emerging research shows that variants in GLP-1 receptor genes, FTO, MC4R, and GIPR pathways influence how individuals respond metabolically to GLP-1 therapy. These genetic predispositions do not determine whether someone will be prescribed GLP-1, but they may help explain individual variation in appetite suppression, weight loss trajectory, and metabolic improvement. PlexusDx Precision Peptide Genetic Test identifies key variants in these pathways to provide context for provider conversations.

A patient with genetic variants associated with lower GLP-1R signaling efficiency may still benefit from GLP-1 therapy, but providers might anticipate a different response curve or consider combination approaches. Conversely, variants linked to higher genetic predisposition for obesity (FTO rs9939609) may indicate stronger metabolic benefit from GLP-1 initiation. Genetic context should be interpreted alongside clinical biomarkers, not in isolation.

Safety Screening, Contraindications, and Who Should Avoid GLP-1

Absolute contraindications include personal or family history of medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia type 2 (MEN2). Cautions apply to severe kidney disease (eGFR <30), active pancreatitis, or uncontrolled diabetic ketoacidosis. Pregnancy is a contraindication; women of childbearing age should use contraception during treatment. Providers must exclude thyroid or pancreatic malignancy before initiating therapy.

Relative cautions include history of gastroparesis, severe dehydration risk, or unstable cardiovascular disease. Patients on insulin or other diabetes medications need dose adjustments to prevent hypoglycemia. Individuals with eating disorders or a history of restrictive eating should undergo psychological evaluation before GLP-1 initiation, as appetite suppression may interact with disordered patterns. Comprehensive provider screening mitigates these risks substantially.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes to reveal individual predispositions in peptide-signaling pathways. These insights may help provide context for why two patients with identical BMI or A1C levels may experience different metabolic responses to GLP-1 therapy. Genetic predisposition does not predict exact medication response, but it can support a more informed conversation with a qualified provider about treatment expectations.

The test identifies genetic variants associated with appetite regulation, weight distribution, and metabolic flexibility—factors that influence GLP-1 candidacy discussions and post-initiation monitoring. For example, patients with FTO variants linked to higher obesity predisposition may see earlier metabolic benefits from GLP-1, while those with specific GLP1R variants might require adjusted dosing or combination strategies. This information is meant to be interpreted by a qualified healthcare provider alongside clinical biomarkers.

Understanding your genetic peptide-pathway predispositions can strengthen your prescription conversation with a provider by contextualizing your individual metabolic profile. Rather than a one-size-fits-all approach, this personalized framework allows providers to set realistic goals, anticipate side effects, and adjust treatment plans based on both genetic and biomarker evidence. PlexusDx supports this precision approach through compounded GLP-1 and tirzepatide options tailored to individual needs.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the minimum BMI required to be prescribed GLP-1?

FDA-approved GLP-1 medications require BMI ≥30 or BMI ≥27 with weight-related comorbidities (hypertension, sleep apnea, diabetes). Compounded formulations may follow similar frameworks, though prescribing practices vary. Your provider evaluates overall metabolic health, not BMI alone.

Can I be prescribed GLP-1 if I have prediabetes but no type 2 diabetes diagnosis?

Some providers prescribe GLP-1 off-label for prediabetes (A1C 5.7–6.4%), particularly with additional risk factors like metabolic syndrome or family history. Insurance coverage is less predictable for prediabetes. Discuss individual risk factors with your provider to evaluate whether GLP-1 aligns with your health plan.

How much does GLP-1 treatment cost at PlexusDx?